Bioverativ Therapeutics Inc.

Puget Sound Blood Center

Bayer Healthcare LLC

Biogen Idec Hemophilia Inc.

Tissue Repair Company

Biogen Hemophilia Inc.

Biogen Hemophila Inc.

Glenn Pierce

Haiyan Jiang

Robert T Peters

Samantha Truex

Jurg Sommer

Susan C Low

Jennifer A Dumont

Matt Ottmer

Alvin Luk

Byron McKinney

Karen Nugent

Lian Li

Alan J Bitonti

Tongyao Liu

Neil Josephson

Sriram Krishnamoorthy

Richard L Feldman

Kirk McLean

Xiao-Yan Zhao

Ji-Yun Kim

Junliang Pan

Xin Zhang

Buyue Yang

James Wu

Byron Mckinney

Barbara A Sosnowski

Mark Brader

Alan J Bitoni

Jurg M Sommer

The present disclosure provides methods of administering chimeric and hybrid Factor VIII (FVIII) polypeptides comprising FVIII and Fc to subjects at risk of developing inhibitory FVIII immune responses, including anti-FVIII antibodies and/or cell-mediated immunity. The administration is sufficient to promote coagulation and to induce immune tolerance to FVIII. The chimeric polypeptide can comprise full-length FVIII or a FVIII polypeptide containing a deletion, e.g., a full or partial deletion of the B domain.

Methods of reducing immunogenicity against factor VIII in individuals undergoing factor VIII therapy

The present invention provides methods of administering Factor VIII (processed FVIII, single chain FVIII, or a combination thereof); methods of administering chimeric and hybrid polypeptides comprising Factor VIII; chimeric and hybrid polypeptides comprising Factor VIII; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.

Factor VIII chimeric and hybrid polypeptides, and methods of use thereof

The present invention provides methods of dosing Factor VIII or Factor IX chimeric and hybrid polypeptides. The present invention further provides high-sensitivity methods of quantifying an amount of activated FIX protein in a test sample.

Assays to monitor bleeding disorders

The present invention provides methods of administering Factor VIII; methods of administering chimeric and hybrid polypeptides comprising Factor VIII; chimeric and hybrid polypeptides comprising Factor VIII; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.

Factor VIII-FC chimeric and hybrid polypeptides, and methods of use thereof

The present invention provides methods of administering long-acting Factor IX; methods of administering long-acting, chimeric and hybrid polypeptides comprising Factor IX; and methods of producing such chimeric and hybrid polypeptides using cells.

Methods of using FIX polypeptides

The present invention provides methods of administering Factor IX; methods of administering chimeric and hybrid polypeptides comprising Factor IX; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.

Factor IX polypeptides and methods of use thereof

Targeted coagulation factors comprising a coagulation factor linked with at least one domain that specifically binds to a membrane protein on a blood cell is provided. The disclosed targeted coagulation factors increase the efficiency of coagulation factors and prolong their duration of action and thus, are an improvement for the treatment of hematological diseases such as hemophilia A.

Targeted coagulation factors and method of using the same

Growing community of inventors

Cambridge, MA, United States of America

Glenn Pierce